PECAM1 and endometrial cancer: Lenvatinib in combination with golvatinib (E7050; c-Met, Tie2, and EphB4 inhibitor) reduced the CD31+ endothelial network, SMA+ pericyte network, and disrupted pericyte-mediated vessel stabilization, decreasing the interaction between ECs and pericytes in thyroid and endometrial cancer models [253].